Eli Lilly and Company is trading 3.24% up at $1,161.70 on continued momentum in its obesity and diabetes franchise and strong institutional demand.
- Renewed enthusiasm around the company’s growth pipeline is fueling investor interest despite a lack of fresh company-specific catalysts.
- The stock is displaying notable relative strength against a softer market backdrop, with the S&P 500 down 1.02% and the Nasdaq Composite down 1.81%.